Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $21.22

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Rating) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $21.22.

A number of research analysts have issued reports on the company. Chardan Capital boosted their target price on Immunovant from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Sunday, February 5th. HC Wainwright increased their price target on Immunovant from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, February 7th. Truist Financial raised their target price on Immunovant to $30.00 in a report on Thursday, November 17th. Cantor Fitzgerald initiated coverage on Immunovant in a report on Wednesday, February 15th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Wells Fargo & Company raised Immunovant from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $10.00 to $27.00 in a research report on Monday, January 2nd.

Insider Buying and Selling

In other Immunovant news, CEO Peter Salzmann sold 4,021 shares of Immunovant stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $16.80, for a total value of $67,552.80. Following the completion of the sale, the chief executive officer now owns 993,932 shares of the company’s stock, valued at approximately $16,698,057.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Julia G. Butchko sold 60,490 shares of the company’s stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $16.79, for a total transaction of $1,015,627.10. Following the sale, the insider now directly owns 331,419 shares in the company, valued at approximately $5,564,525.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Peter Salzmann sold 4,021 shares of the company’s stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $16.80, for a total transaction of $67,552.80. Following the transaction, the chief executive officer now owns 993,932 shares in the company, valued at $16,698,057.60. The disclosure for this sale can be found here. Insiders sold a total of 79,714 shares of company stock worth $1,356,505 in the last three months. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunovant

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its position in shares of Immunovant by 0.9% in the first quarter. BlackRock Inc. now owns 3,353,866 shares of the company’s stock valued at $18,479,000 after purchasing an additional 28,865 shares during the period. Point72 Asset Management L.P. acquired a new position in Immunovant during the 3rd quarter worth approximately $10,978,000. Federated Hermes Inc. grew its holdings in Immunovant by 281.2% during the 1st quarter. Federated Hermes Inc. now owns 1,903,894 shares of the company’s stock worth $10,491,000 after acquiring an additional 1,404,404 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Immunovant by 22.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,297,608 shares of the company’s stock valued at $23,032,000 after buying an additional 239,149 shares in the last quarter. Finally, Cowen AND Company LLC acquired a new position in shares of Immunovant in the 4th quarter valued at $22,188,000. Hedge funds and other institutional investors own 32.77% of the company’s stock.

Immunovant Stock Performance

Shares of IMVT opened at $15.55 on Friday. The stock has a fifty day moving average price of $17.90 and a two-hundred day moving average price of $13.08. Immunovant has a 52-week low of $3.14 and a 52-week high of $20.24. The company has a market cap of $2.03 billion, a price-to-earnings ratio of -9.37 and a beta of 1.00.

Immunovant Company Profile

(Get Rating)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.